

Materials Design Analysis Reporting (MDAR) **Checklist for Authors**

The [MDAR framework](#) establishes a minimum set of requirements in transparent reporting mainly applicable to studies in the life sciences.

eLife asks authors to **provide detailed information within their article** to facilitate the interpretation and replication of their work. Authors can also upload supporting materials to comply with relevant reporting guidelines for health-related research (see [EQUATOR Network](#)), life science research (see the [BioSharing Information Resource](#)), or animal research (see the [ARRIVE Guidelines](#) and the [STRANGE Framework](#); for details, see *eLife's* [Journal Policies](#)). Where applicable, authors should refer to any relevant reporting standards materials in this form.

For all that apply, please note **where in the article** the information is provided. Please note that we also collect information about data availability and ethics in the submission form.

Materials:

Newly created materials	Indicate where provided: section/figure legend	N/A
The manuscript includes a dedicated "materials availability statement" providing transparent disclosure about availability of newly created materials including details on how materials can be accessed and describing any restrictions on access.	Data made available upon request. Imaging data is stored on Dropbox, the link will be shared with those who ask for it.	

Antibodies	Indicate where provided: section/figure legend	N/A
For commercial reagents, provide supplier name, catalogue number and RRID , if available.	Figure 2 Mouse anti-a-tubulin, Sigma Cat # T9026; RRID: AB_477593 Rabbit anti-Pins, F. Matsuzaki 0100-1AP Rabbit anti-GFP, Abcam, ab290 Rat anti-E-cadherin, Developmental Studies Hybridoma Bank (DSHB) Goat anti-Mouse Alexa Fluor 488, Invitrogen Cat #A32723 Goat anti-Mouse Alexa Fluor 568, Invitrogen Cat # A-11004 Goat anti-Rabbit Alexa Fluor 647, Invitrogen Cat # A32733	

DNA and RNA sequences	Indicate where provided: section/figure legend	N/A
Short novel DNA or RNA including primers, probes: Sequences should be included or deposited in a public repository.	<p>Figure 4- figure supplement 1 Toll 2 F: AGTTTGAATCGAAACGCGAG Toll 2 R: GGACACTGCACCGGATGT Toll 6 F: ATCGGCCAAAAAGAGCAGTA Toll 6 R: AGCAGCGTGTGCAGATTATT Toll 8 F: ATGCGTACCATTTTCCTACCA Toll 8 R: TTTTACTCTTCGCTTTTTCGC</p> <p>Figure 7- figure supplement 1 Sna F: CGGAACCGAAACGTGACTAT Sna R: GCGGTAGTTTTTGGCATGAT</p>	

Cell materials	Indicate where provided: section/figure legend	N/A
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID.		N/A
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		N/A

Experimental animals	Indicate where provided: section/figure legend	N/A															
Laboratory animals or Model organisms: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID.	<table border="1"> <tr> <td data-bbox="416 1552 708 1637">Jupiter::GFP</td> <td data-bbox="708 1552 882 1637">Bloomington Drosophila Stock Center</td> <td data-bbox="882 1552 1310 1637">Figure 1, Figure 4- figure supplement 1, Figure 6- figure supplement 2</td> </tr> <tr> <td data-bbox="416 1637 708 1697">y,w; Sp/Cyo; Utr::GFP, sqh::Ch[a11]/TM3, Sb</td> <td data-bbox="708 1637 882 1697">This lab</td> <td data-bbox="882 1637 1310 1697">Figure 1</td> </tr> <tr> <td data-bbox="416 1697 708 1816">w; mat67; ubi-Pins:YFP, Pins[62]/TM6, Tb, Hu</td> <td data-bbox="708 1697 882 1816">This study, original stock from Chanet et al. 2017</td> <td data-bbox="882 1697 1310 1816">Figure 2, Figure 3, Figure 5, Figure 6, Figure 7, Figure 2- figure supplement 1</td> </tr> <tr> <td data-bbox="416 1816 708 1877">mat67; mat15, gap43::mCh</td> <td data-bbox="708 1816 882 1877">Vasquez et al., 2014</td> <td data-bbox="882 1816 1310 1877">Figure 2, Figure 3- figure supplement 2</td> </tr> <tr> <td data-bbox="416 1877 708 1960">OreR</td> <td data-bbox="708 1877 882 1960">Bloomington Drosophila Stock Center</td> <td data-bbox="882 1877 1310 1960">Figure 2</td> </tr> </table>	Jupiter::GFP	Bloomington Drosophila Stock Center	Figure 1, Figure 4- figure supplement 1, Figure 6- figure supplement 2	y,w; Sp/Cyo; Utr::GFP, sqh::Ch[a11]/TM3, Sb	This lab	Figure 1	w; mat67; ubi-Pins:YFP, Pins[62]/TM6, Tb, Hu	This study, original stock from Chanet et al. 2017	Figure 2, Figure 3, Figure 5, Figure 6, Figure 7, Figure 2- figure supplement 1	mat67; mat15, gap43::mCh	Vasquez et al., 2014	Figure 2, Figure 3- figure supplement 2	OreR	Bloomington Drosophila Stock Center	Figure 2	
Jupiter::GFP	Bloomington Drosophila Stock Center	Figure 1, Figure 4- figure supplement 1, Figure 6- figure supplement 2															
y,w; Sp/Cyo; Utr::GFP, sqh::Ch[a11]/TM3, Sb	This lab	Figure 1															
w; mat67; ubi-Pins:YFP, Pins[62]/TM6, Tb, Hu	This study, original stock from Chanet et al. 2017	Figure 2, Figure 3, Figure 5, Figure 6, Figure 7, Figure 2- figure supplement 1															
mat67; mat15, gap43::mCh	Vasquez et al., 2014	Figure 2, Figure 3- figure supplement 2															
OreR	Bloomington Drosophila Stock Center	Figure 2															

	<table border="1"> <tr> <td>y; mat67, Sqh::Cherry[B1]; GFP::CLIP170/TM3, Sb</td> <td>This lab</td> <td>Figure 3, Figure 4, Figure 6, Figure 7, Figure 3- figure supplement 3, Figure 4- figure supplement 2, Figure 6- figure supplement 1</td> </tr> <tr> <td>w[*]; P{w[+mC]=UAS-ChRFP-Tub}2</td> <td>Bloomington Drosophila Stock Center</td> <td>Figure 6, Figure 7</td> </tr> <tr> <td>UAS-Pins::GFP</td> <td>Chanet et al. 2017</td> <td>Figure 3</td> </tr> <tr> <td>UAS-myrPins::GFP</td> <td>Chanet et al. 2017</td> <td>Figure 3, Figure 3- figure supplement 2</td> </tr> <tr> <td>y[1] sc[*] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.GL01052}attP2 (Rh3 shRNA control line)</td> <td>Perkins et al., 2015</td> <td>Figure 4, Figure 5, Figure 4- figure supplement 2</td> </tr> <tr> <td>y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.HMS00317} attP2 (alpha-catenin shRNA)</td> <td>Perkins et al., 2015</td> <td>Figure 4, Figure 5, Figure 4- figure supplement 2</td> </tr> <tr> <td>y[1] sc* v[1] sev[21]; P{TRiP.GL00633}attP40 (Cno shRNA line 1)</td> <td>Perkins et al., 2015</td> <td>Figure 4</td> </tr> <tr> <td>y[1] sc* v[1] sev[21]; P{TRiP.HMS00239}attP2 (Cno shRNA line 2)</td> <td>Perkins et al., 2015</td> <td>Figure 4</td> </tr> <tr> <td>y,w; FRT[G13],18w[076]/cyo, Twis::GFP; Toll6[54]95-1, Toll8[89], spider::GFP/eve::YFP</td> <td>This study, original stocks from Pare et al. 2014</td> <td>Figure 4- figure supplement 1</td> </tr> </table>	y; mat67, Sqh::Cherry[B1]; GFP::CLIP170/TM3, Sb	This lab	Figure 3, Figure 4, Figure 6, Figure 7, Figure 3- figure supplement 3, Figure 4- figure supplement 2, Figure 6- figure supplement 1	w[*]; P{w[+mC]=UAS-ChRFP-Tub}2	Bloomington Drosophila Stock Center	Figure 6, Figure 7	UAS-Pins::GFP	Chanet et al. 2017	Figure 3	UAS-myrPins::GFP	Chanet et al. 2017	Figure 3, Figure 3- figure supplement 2	y[1] sc[*] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.GL01052}attP2 (Rh3 shRNA control line)	Perkins et al., 2015	Figure 4, Figure 5, Figure 4- figure supplement 2	y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.HMS00317} attP2 (alpha-catenin shRNA)	Perkins et al., 2015	Figure 4, Figure 5, Figure 4- figure supplement 2	y[1] sc* v[1] sev[21]; P{TRiP.GL00633}attP40 (Cno shRNA line 1)	Perkins et al., 2015	Figure 4	y[1] sc* v[1] sev[21]; P{TRiP.HMS00239}attP2 (Cno shRNA line 2)	Perkins et al., 2015	Figure 4	y,w; FRT[G13],18w[076]/cyo, Twis::GFP; Toll6[54]95-1, Toll8[89], spider::GFP/eve::YFP	This study, original stocks from Pare et al. 2014	Figure 4- figure supplement 1	
y; mat67, Sqh::Cherry[B1]; GFP::CLIP170/TM3, Sb	This lab	Figure 3, Figure 4, Figure 6, Figure 7, Figure 3- figure supplement 3, Figure 4- figure supplement 2, Figure 6- figure supplement 1																											
w[*]; P{w[+mC]=UAS-ChRFP-Tub}2	Bloomington Drosophila Stock Center	Figure 6, Figure 7																											
UAS-Pins::GFP	Chanet et al. 2017	Figure 3																											
UAS-myrPins::GFP	Chanet et al. 2017	Figure 3, Figure 3- figure supplement 2																											
y[1] sc[*] v[1]; P{y[+t7.7] v[+t1.8]=TRiP.GL01052}attP2 (Rh3 shRNA control line)	Perkins et al., 2015	Figure 4, Figure 5, Figure 4- figure supplement 2																											
y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.HMS00317} attP2 (alpha-catenin shRNA)	Perkins et al., 2015	Figure 4, Figure 5, Figure 4- figure supplement 2																											
y[1] sc* v[1] sev[21]; P{TRiP.GL00633}attP40 (Cno shRNA line 1)	Perkins et al., 2015	Figure 4																											
y[1] sc* v[1] sev[21]; P{TRiP.HMS00239}attP2 (Cno shRNA line 2)	Perkins et al., 2015	Figure 4																											
y,w; FRT[G13],18w[076]/cyo, Twis::GFP; Toll6[54]95-1, Toll8[89], spider::GFP/eve::YFP	This study, original stocks from Pare et al. 2014	Figure 4- figure supplement 1																											
Animal observed in or captured from the field: Provide species, sex, and age where possible.		N/A																											

Plants and microbes	Indicate where provided: section/figure legend	N/A
Plants: provide species and strain, ecotype and cultivar where relevant, unique accession number if available, and source (including location for collected wild specimens).		N/A
Microbes: provide species and strain, unique accession number if available, and source.		N/A

Human research participants	Indicate where provided: section/figure legend) or state if these demographics were not collected	N/A
If collected and within the bounds of privacy constraints report on age, sex, gender and ethnicity for all study participants.		N/A

Design:

Study protocol	Indicate where provided: section/figure legend	N/A
If the study protocol has been pre-registered, provide DOI. For clinical trials, provide the trial registration number OR cite DOI.		N/A

Laboratory protocol	Indicate where provided: section/figure legend	N/A
Provide DOI OR other citation details if detailed step-by-step protocols are available.		N/A

Experimental study design (statistics details) *		
For in vivo studies: State whether and how the following have been done	Indicate where provided: section/figure legend. If it could have been done, but was not, write "not done"	N/A
Sample size determination	Sample size was determined by matching or exceeding standards in the field. For live and fixed imaging of spindles we aimed for a sample size of 10 embryos and over 100 spindles. Some experiments had lower n (triple mutant generation, laser ablations and injections) due to difficulty in setting up and performing the experiments, making higher ns less feasible. For live imaging of Pins, we aimed for 3 embryos and around 30 cells.	

Randomisation	Not done	
Blinding	Not done	
Inclusion/exclusion criteria	All measurable samples were included	

Sample definition and in-laboratory replication	Indicate where provided: section/figure legend	N/A
State number of times the experiment was replicated in the laboratory.	For live and fixed imaging of spindles we had around 10 replicate embryos from 2-3 replicate crosses. More difficult experiments (triple mutant generation, laser ablation, and injections) had fewer replicates, around 3-5, from 2 replicate crosses. For live imaging of Pins, we had 3 replicate embryos from 2 replicate crosses.	
Define whether data describe technical or biological replicates.	Data describe biological replicates, which we define as distinct samples that show biological variation	

Ethics	Indicate where provided: section/submission form	N/A
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		N/A

Dual Use Research of Concern (DURC)	Indicate where provided: section/submission form	N/A
If study is subject to dual use research of concern regulations, state the authority granting approval and reference number for the regulatory approval.		N/A

Analysis:

Attrition	Indicate where provided: section/figure legend	N/A
Describe whether exclusion criteria were pre-established. Report if sample or data points were omitted from analysis. If yes, report if this was due to attrition or intentional exclusion and provide justification.	All measurable samples was analyzed	

Statistics	Indicate where provided: section/figure legend	N/A
Describe statistical tests used and justify choice of tests.	The Mann-Whitney statistical test was chosen. This test was chosen because it is a non-parametric test that compares the distribution of two samples.	

Data availability	Indicate where provided: section/submission form	N/A
For newly created and reused datasets, the manuscript includes a data availability statement that provides details for access (or notes restrictions on access).		N/A
When newly created datasets are publicly available, provide accession number in repository OR DOI and licensing details where available.		N/A
If reused data is publicly available provide accession number in repository OR DOI, OR URL, OR citation.		N/A

Code availability	Indicate where provided: section/figure legend	N/A
For any computer code/software/mathematical algorithms essential for replicating the main findings of the study, whether newly generated or re-used, the manuscript includes a data availability statement that provides details for access or notes restrictions.		N/A
Where newly generated code is publicly available, provide accession number in repository, OR DOI OR URL and licensing details where available. State any restrictions on code availability or accessibility.		N/A

If reused code is publicly available provide accession number in repository OR DOI OR URL, OR citation.	N/A
---	-----

Reporting:

The MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives.

Adherence to community standards	Indicate where provided: section/figure legend	N/A
State if relevant guidelines (e.g., ICMJE, MIBBI, ARRIVE, STRANGE) have been followed, and whether a checklist (e.g., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.		N/A

* We provide the following guidance regarding transparent reporting and statistics; we also refer authors to [Ten common statistical mistakes to watch out for when writing or reviewing a manuscript](#).

Sample-size estimation

- You should state whether an appropriate sample size was computed when the study was being designed
- You should state the statistical method of sample size computation and any required assumptions
- If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use

Replicates

- You should report how often each experiment was performed
- You should include a definition of biological versus technical replication
- The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates
- If you encountered any outliers, you should describe how these were handled
- Criteria for exclusion/inclusion of data should be clearly stated
- High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)

Statistical reporting

- Statistical analysis methods should be described and justified
- Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10)
- For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect size (e.g., Pearson's r, Cohen's d)
- Report exact p-values wherever possible alongside the summary statistics and 95% confidence intervals. These should be reported for all key questions and not only when the p-value is less than 0.05.

Group allocation

- Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied
- Indicate if masking was used during group allocation, data collection and/or data analysis